Literature DB >> 10517560

Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS.

D Hensley1, J T Cody.   

Abstract

A method is described for the simultaneous determination of the ratio of l- and d-enantiomers of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in urine. The assay uses liquid-liquid extraction followed by derivatization with trifluoroacetyl-l-prolyl chloride (l-TPC) and analysis by gas chromatography-mass spectrometry. The assay was developed using prepared samples containing varying concentrations of each of the analytes over a range of percentages of each enantiomer. Results showed the method to provide accurate and reliable results in samples containing > or = 10 ng/mL amphetamine and methamphetamine and > or = 25 ng/mL MDA, MDMA, and MDEA. The assay was used to analyze urine samples from subjects of a controlled MDMA study. Results for each of the eight subjects showed a greater percentage of the l-enantiomer of MDMA initially, and the percentage increased with time postdose. Analysis of the metabolite MDA revealed that the proportion of d-enantiomer was initially greater than the l-enantiomer followed by a gradual increase in the proportion of l-enantiomer until it exceeded the amount of the d-enantiomer. In all cases, the l-MDA exceeded the d-MDA within the first 36 h postdose.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517560     DOI: 10.1093/jat/23.6.518

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  3 in total

1.  Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

Authors:  Andrea E Schwaninger; Markus R Meyer; Marilyn A Huestis; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2011-07       Impact factor: 1.982

2.  Chirality and structure-selective MALDI using mold matrix.

Authors:  Yosuke Fujii; Jiawei Xu; Tatsuya Fujino
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

Review 3.  Current and Emerging Treatments for Methamphetamine Use Disorder.

Authors:  Anna Moszczynska
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.